Today the FDA announced a new drug approval for Abilify MyCite, complete with a sensor that can digitally track whether or not a patient has taken their medication. The pill includes a sensor that can be ingested and can alert doctors if a patient taken or missed their dose.
Abilify is most commonly taken for patients diagnosed with schizophrenia and bipolar I disorder. The patient must wear a patch that can transmit data via a mobile application on their smart phone or can give permission to share the updates with a designated family member or doctor. Individuals with permission to access the information can also do so in an online portal.
“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” said Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”
It’s a known problem that patients taking medications for a wide variety of reasons stop taking their doses when they start to feel better without realizing the reason for their overall improvement is due to their regular adherence to taking proper doses. While there is no correlation yet between the new tracking capability for Abilify and a patient’s willingness to share the information with prescribers, hopefully in the future, hopefully this will help keep patients on track.
Read the full press release from the FDA Here.